Positive Clinical Results for Alzheimer’s Amyloid-Clearing Drug – Lecanemab Poised for FDA Approval
Alzheimer’s Drug Discovery Foundation announced that the amyloid-clearing drug lecanemab will be a positive step in the treatment of Alzheimer’s disease based on study results presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference and published in The New England Journal of Medicine.Positive results from new amyloid-clearing drug represent a starting point for <span class="glossaryLink" aria-describedby="tt" data-cmtooltip="<div…